Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy

NCT06391775 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated due to strategic decision

Conditions

Malignant Solid Tumor

Interventions

BIOLOGICAL: GEN1055
BIOLOGICAL: Pembrolizumab
DRUG: Standard Chemotherapy

Sponsor

Genmab

Collaborators

[object Object]